Trial Profile
A 4-week multicentre randomized double-blind double-dummy parallel group ambulatory blood pressure monitoring study to investigate whether treatment with lumiracoxib 100 mg once daily results in an improved 24-hour blood pressure profile compared to ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Lumiracoxib (Primary) ; Ibuprofen
- Indications Hypertension; Osteoarthritis
- Focus Pharmacodynamics
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 13 Jul 2007 Status changed from in progress to completed.
- 13 Jul 2007 Results have been reported.
- 01 Dec 2006 Status change